Approval of Sovaldi triggered active new drug competition
‘Sovaldi(sofosbuvir), a hepatitis C treatment, has been approved.
According to the industry concerned on the 11th, Gilead Sciences Korea’s Sovaldi has acquired approval from Ministry of Food and Drug Safety(MFDS) on the 10th.
Gilead turned in an application for a new drug last January, and in t...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
